|
Panel Backs Bone Graft Device Despite FDA Concerns
An FDA advisory panel has backed BioMimetic Therapeutics’ investigational bone graft device, which uses a growth factor protein to regrow bones in the foot and ankle, despite FDA questions about the intended patient population.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives